Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration
WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.
- WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.
- This patent further protects Tome’s foundational PGI technology, integrase-mediated PGI (I-PGI), describes a system capable of performing I-PGI in a mammalian cell, and is exclusively licensed to Tome from MIT.
- “Today’s issuance marks the fourth US patent granted that encompasses our I-PGI technology, strengthening our patent portfolio and broadening our exclusivity,” said Rahul Kakkar, MD, President and Chief Executive Officer of Tome.
- Together, with US Patent 11,952,571, these patents cover methods and systems relating to the use of a Cas 9 nickase, reverse transcriptase and an integrase to integrate DNA sequences into programmed locations.